Aurinia Pharmaceuticals (AUPH) Competitors

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, community ranking, earnings, profitability, valuation, institutional ownership and risk.

Which has more volatility & risk, AUPH or PCVX?

Aurinia Pharmaceuticals has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.

Do institutionals and insiders hold more shares of AUPH or PCVX?

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 4.3% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 3.1% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Is AUPH or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to Aurinia Pharmaceuticals' net margin of -10.23%. Aurinia Pharmaceuticals' return on equity of -4.41% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	-10.23%	-4.41%	-3.07%
Vaxcyte	N/A	-23.53%	-22.20%

Does the MarketBeat Community prefer AUPH or PCVX?

Aurinia Pharmaceuticals received 522 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 78.57% of users gave Vaxcyte an outperform vote while only 73.41% of users gave Aurinia Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Aurinia Pharmaceuticals	Outperform Votes 577 73.41%	Underperform Votes 209 26.59%
Vaxcyte	Outperform Votes 55 78.57%	Underperform Votes 15 21.43%

Do analysts prefer AUPH or PCVX?

Aurinia Pharmaceuticals presently has a consensus price target of $11.50, suggesting a potential upside of 40.24%. Vaxcyte has a consensus price target of $136.50, suggesting a potential upside of 287.34%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts clearly believe Vaxcyte is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Vaxcyte	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.10

Which has better earnings & valuation, AUPH or PCVX?

Aurinia Pharmaceuticals has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$235.13M	4.77	-$78.02M	$0.05	164.00
Vaxcyte	N/A	N/A	-$402.27M	-$3.80	-9.27

Does the media prefer AUPH or PCVX?

In the previous week, Vaxcyte had 11 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 17 mentions for Vaxcyte and 6 mentions for Aurinia Pharmaceuticals. Vaxcyte's average media sentiment score of 1.41 beat Aurinia Pharmaceuticals' score of 0.92 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vaxcyte beats Aurinia Pharmaceuticals on 11 of the 18 factors compared between the two stocks.